Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
about
Mitochondrial metabolic remodeling in response to genetic and environmental perturbationsEpigenetic regulators and their impact on therapy in acute myeloid leukemiaEpigenetic regulators as promising therapeutic targets in acute myeloid leukemiaEpigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic DiseasesMolecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment2-Hydoxyglutarate: D/Riving Pathology in gLiomaSClinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasmsThe genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemiaMinimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Gene mutation patterns in patients with minimally differentiated acute myeloid leukemia.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesGlial progenitors as targets for transformation in glioma.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicGenetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.The molecular basis of myeloid malignancies.Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.Cancer stem cells as a target population for drug discovery.Investigational cancer drugs targeting cell metabolism in clinical development.A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.Rational Combinations of Targeted Agents in AMLThe Warburg effect: a balance of flux analysisTargeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondTET proteins and 5-methylcytosine oxidation in hematological cancersDetection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Digging deep into "dirty" drugs - modulation of the methylation machinery.High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.The Impact of DNA Methylation in Hematopoietic Malignancies.Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemiaIsocitrate dehydrogenase mutations in myeloid malignancies.Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateStem cell origin of myelodysplastic syndromes.Chromatin modifiers and the promise of epigenetic therapy in acute leukemiaInvestigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.The mechanistic role of DNA methylation in myeloid leukemogenesis.
P2860
Q26747718-B43EB65B-32D5-452A-8A83-ECEAEF2534D0Q26765402-B3D07674-C640-4940-9C06-3FD126B4DC2EQ26865149-ECE79F7D-3C2C-4C9D-8BC7-DC9099F59E97Q28079715-24B1030B-E329-4DBB-88F7-47FC6BD9F9E8Q28081657-C3C67CC4-824F-4356-AD0F-6F7EEED84EC5Q28087807-550377DC-6F44-434F-B3DE-0CA01F747F07Q29039802-D8D8118B-3A2C-4509-8756-23E29BFBF011Q33796552-0DEC7A15-0B1A-476F-BFF8-D46DC41DF032Q33832709-6D221577-8034-46CD-A927-3F7D39F058B8Q34347096-2DBE54B6-5813-4554-A1E9-1DFF6FA40F52Q34661033-A85D40AD-11C0-4723-B7A8-983310F7A16EQ34735661-A43E8D08-BF82-42B1-87BF-51EAAB425299Q34817365-EF488777-8615-440B-A4AD-E157005C8C9EQ34876800-A04D3931-5565-49CB-8652-BA618A0C748FQ35067345-79000309-F29C-4B08-8E4C-AB4575C12C3FQ35103708-348AAEEF-CA31-4895-9765-F4EC25F3B690Q35234477-1A517205-934B-46DC-9165-74A2489A356CQ35390334-8A80D7FF-BF70-427C-AC17-B62AE0F7D2BDQ35615701-11AACCAB-FA7A-4FB6-9DED-B3351592BBECQ35748498-59E84F12-AAEA-4D19-993B-AC770C0C2180Q35750491-37A14E88-4D04-481A-83B8-F6E9B4A3BED4Q35865839-83DFF55D-931B-4174-9682-D0F752E81371Q35967446-8BB7E8CD-54EB-408E-B009-45CA73191BE7Q36197509-49E27712-BB5B-491E-A5E0-FA4B664BBB34Q36240610-E85FF431-0776-408C-B558-AA6330A2F0F3Q36523796-4CB0C333-D426-46D0-94EE-21DD314B1229Q36545112-6B89772D-45A0-4A7B-ACF2-749CADC359BEQ36561772-21BE4660-BC63-403C-8F44-967786860A85Q36724810-1ECF6405-4A6F-4118-8F41-48BCDAED4CCDQ36805635-D55C11C2-F0DE-45EC-A2EE-DFDB2650E19AQ37220616-8C051FAA-0F6B-4D21-99A4-EE8786B41389Q37221579-F9BD325A-9696-482F-9118-99396C66386FQ37252482-AFDB3494-0E86-4952-A839-BF6735161EF3Q37625630-99E5AD9A-1ED3-4112-A875-74E4A8CAD050Q37632016-A6EA1B68-2268-46AE-84D8-9E834EF136CEQ38171230-13F8CE01-8246-4B92-86C8-0B5D0A3EDB50Q38194444-D08A4693-D3E4-4A43-A31D-ECEA2F12465EQ38214120-0B419C0C-A7F6-4A51-91CD-3C29D53914D9Q38218055-5C03FD22-CFE9-455F-99AE-152C13259762Q38218971-31290396-977D-4D12-B657-10F65B81F698
P2860
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@en
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@nl
type
label
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@en
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@nl
prefLabel
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@en
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@nl
P2093
P50
P1433
P1476
Mutant IDH1 promotes leukemoge ...... fically targeted in human AML.
@en
P2093
Adrian Schwarzer
Amit Sharma
Arnold Ganser
Eduard A Struys
Erwin E Jansen
Felicitas Thol
Haiyang Yun
Johann Meyer
Jürgen Krauter
Kerstin Görlich
P304
P356
10.1182/BLOOD-2013-03-491571
P407
P577
2013-08-16T00:00:00Z